Key result
SC-40230 shows minimal hemodynamic depression and weaker negative inotropy versus disopyramide or mexiletine in preclinical models.
Why the study?
The cardiovascular and haemodynamic effects of the new anti-arrhythmic agent SC-40230 were assessed to evaluate its side effect potential compared to existing drugs.
What are the cardiovascular and haemodynamic effects of the new anti-arrhythmic agent SC-40230 in preclinical models?
What are the cardiovascular and haemodynamic effects of the new anti-arrhythmic agent SC-40230 in preclinical models?
SC-40230 demonstrates a favorable preclinical hemodynamic profile with less negative inotropic effect compared to existing anti-arrhythmics like disopyramide.
Answers are grounded in this paper and cite their sources.
Supports preclinical advancement of SC-40230 for its favorable hemodynamics; leaves open translation to human arrhythmias.
The cardiac and general haemodynamic effects of SC-40230, a newly developed anti-arrhythmic agent with both class 1a and 1b properties, were assessed in two different types of experiments using anaesthetised dogs, and in experiments using isolated cat papillary muscles. At the canine anti-arrhythmic dose (9 mg.kg-1 intravenously), SC-40230 decreased the maximum rate of rise of the left ventricular pressure (LV dP/dtmax) by 20%. It decreased heart rate slightly, and lowered (greater than 10%) blood pressure only at doses greater than the canine anti-arrhythmic dose. In these experiments there were dose dependent increases in the P-R interval and the QRS duration. In isolated cat papillary muscles, SC-40230 had a weak negative inotropic effect (IC20 = 3.3 X 10(-5) mol.litre-1) which was less than that previously reported for disopyramide phosphate (IC20 = 1.8 X 10(-5) mol.litre-1) or mexiletine (IC20 = 2.1 X 10(-5) mol.litre-1). These findings suggest SC-40230 has a minimal cardiovascular and haemodynamic side effect potential in its anti-arrhythmic dose range. If these results are confirmed in clinical studies, SC-40230 may have an improved side effect profile versus other anti-arrhythmic drugs such as disopyramide.
No takes yet. Share an insight, caveat, or question.
Frederick et al. (1989) studied this question. SC-40230 vs. disopyramide phosphate or mexiletine was evaluated on Cardiac and general haemodynamic effects. In animal models, SC-40230 demonstrated a weak negative inotropic effect and minimal haemodynamic side effects at its anti-arrhythmic dose compared to disopyramide and mexiletine.
Synapse has enriched 10 related papers. Consider them for comparative context: